Chen X - Search Results

1

Association between various insulin resistance indices and cardiovascular disease in middle-aged and elderly individuals: evidence from two prospectives nationwide cohort surveys.

Li Y, Li H, Chen X, Liang X. Li Y, et al. Among authors: chen x. Front Endocrinol (Lausanne). 2024 Nov 22;15:1483468. doi: 10.3389/fendo.2024.1483468. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39649228 Free PMC article.

2

Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.

Liang X, Chen X, Li H, Li Y. Liang X, et al. Among authors: chen x. Front Endocrinol (Lausanne). 2023 May 9;14:1137464. doi: 10.3389/fendo.2023.1137464. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37229447 Free PMC article.

3

Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.

Li Y, Liang X, Li H, Yang T, Guo S, Chen X. Li Y, et al. Among authors: chen x. Front Pharmacol. 2022 Jul 19;13:906956. doi: 10.3389/fphar.2022.906956. eCollection 2022. Front Pharmacol. 2022. PMID: 35928269 Free PMC article.

4

Efficacy and safety of optional parenteral antimicrobial therapy for complicated skin and soft tissue infections: A systematic review and Bayesian network meta-analysis.

Li H, Liang X, Mo G, Guo S, Chen X, Li Y. Li H, et al. Among authors: chen x. Medicine (Baltimore). 2022 Aug 26;101(34):e30120. doi: 10.1097/MD.0000000000030120. Medicine (Baltimore). 2022. PMID: 36042624 Free PMC article.

5

Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis.

Li Y, Liang X, Li H, Chen X. Li Y, et al. Among authors: chen x. Cancer. 2022 Nov 15;128(22):3995-4003. doi: 10.1002/cncr.34457. Epub 2022 Sep 16. Cancer. 2022. PMID: 36111952 Free article.

6

Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis.

Li Y, Liang X, Yang T, Guo S, Chen X. Li Y, et al. Among authors: chen x. Front Oncol. 2022 Sep 26;12:878054. doi: 10.3389/fonc.2022.878054. eCollection 2022. Front Oncol. 2022. PMID: 36226060 Free PMC article.

7

Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis.

Li Y, Liang X, Li H, Chen X. Li Y, et al. Among authors: chen x. Int Immunopharmacol. 2023 Feb;115:109657. doi: 10.1016/j.intimp.2022.109657. Epub 2023 Jan 4. Int Immunopharmacol. 2023. PMID: 36608446 Review.

8

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.

Liang X, Chen X, Li H, Li Y. Liang X, et al. Among authors: chen x. Front Public Health. 2023 Jan 30;11:1009920. doi: 10.3389/fpubh.2023.1009920. eCollection 2023. Front Public Health. 2023. PMID: 36794070 Free PMC article.

9

Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.

Liang X, Chen X, Li H, Liu X, Li Y. Liang X, et al. Among authors: chen x. Front Public Health. 2023 Feb 27;11:1054405. doi: 10.3389/fpubh.2023.1054405. eCollection 2023. Front Public Health. 2023. PMID: 36923040 Free PMC article.

10

Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer.

Liang X, Chen X, Li H, Li Y. Liang X, et al. Among authors: chen x. Front Oncol. 2023 Apr 26;13:1113374. doi: 10.3389/fonc.2023.1113374. eCollection 2023. Front Oncol. 2023. PMID: 37182130 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

118,429 results

Search Page

Filters